Liraglutide is a GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes. Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.
It is an incretin mimic that acts as an agonist at glucagon-like peptide 1 (GLP-1) receptor. It increases glucose-dependent insulin secretion by the pancreatic β-cells, suppresses inappropriately elevated glucagon secretion, increases β-cell growth/replication, and slows gastric emptying. It also decreases food intake by reducing appetite and increasing satiety.
It is an incretin mimic that acts as an agonist at glucagon-like peptide 1 (GLP-1) receptor. It increases glucose-dependent insulin secretion by the pancreatic β-cells, suppresses inappropriately elevated glucagon secretion, increases β-cell growth/replication, and slows gastric emptying. It also decreases food intake by reducing appetite and increasing satiety.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2025 The Doctors Platform. All Right Reserved.
